Drug
S-1+Oxaliplatin
S-1+Oxaliplatin is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
3
75%
Phase Distribution
0
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
3(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(1)
Other(3)
Detailed Status
unknown3
Completed1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 23 (100.0%)
Trials by Status
completed125%
unknown375%
Recent Activity
0 active trials
Showing 4 of 4
unknownphase_2
Efficacy and Safety of S-1 Plus Oxaliplatin in First-line Treatment of Ederly Patients With Advanced Gastric Cancer
NCT04694404
completed
The Predictive Value of Complement C3 in Patients With Advanced Gastric Cancer
NCT02425930
unknownphase_2
The Long-term Effect of D4 Lymphadenectomy for Gastric Cancer
NCT02423278
unknownphase_2
Study of Continuous or Intermittent S-1 Combined With Oxaliplatin in Recurrent or Metastatic Gastric Carcinoma
NCT00515190
Clinical Trials (4)
Showing 4 of 4 trials
NCT04694404Phase 2
Efficacy and Safety of S-1 Plus Oxaliplatin in First-line Treatment of Ederly Patients With Advanced Gastric Cancer
NCT02425930
The Predictive Value of Complement C3 in Patients With Advanced Gastric Cancer
NCT02423278Phase 2
The Long-term Effect of D4 Lymphadenectomy for Gastric Cancer
NCT00515190Phase 2
Study of Continuous or Intermittent S-1 Combined With Oxaliplatin in Recurrent or Metastatic Gastric Carcinoma
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4